Case Based Panel Discussions 2019 - Lung Cancer | CancerGRACE

The Global Resource for Advancing Cancer Education (GRACE)

Where Education is Medicine.

Case Based Panel Discussions 2019 - Lung Cancer

Unresectable NSCLC

Case Based Panel Discussion - Unresectable NSCLC, Should Molecular Tests be Considered, and Would Outcome Effect Treatment Decisions?

Howard (Jack) West, MD

Case Based Panel Discussion - Unresectable NSCLC, In a Frail Patient with Competing Risks, Is the Standard Treatment the Best Approach?

Howard (Jack) West, MD

Case Based Panel Discussion Stage 3 NSCLC - Does Timing of Treatment Make a Difference in Response

Howard (Jack) West, MD

Case Based Panel Discussion - Stage 3 NSCLC Treatment Standard and the Risk of Potential Pneumonitis

Howard (Jack) West, MD

Case Based Panel Discussion - Stage 3 NSCLC Patient with PDL1 Score of 0, Is Immunotherapy Beneficial?

Howard (Jack) West, MD

Case Based Panel Discussion - Stage 3 NSCLC Best Schedule - Durvalumab/Imfinzi in Varying Patients

Howard (Jack) West, MD

Case Based Panel Discussion Stage 3 NSCLC - Tumor Mutational Burden (TMB), and the Value in Testing

Howard (Jack) West, MD

Case Based Panel Discussion - Stage 3 NSCLC - Immunotherapy Combos Checkmate 227 a Treatment Option?

Howard (Jack) West, MD

Case Based Panel Discussions 2019 - Lung Cancer

ALK-Positive

Case Based Panel Discussion - 2019 Alk Positive First Line Treatment

Howard (Jack) West, MD

Case Based Panel Discussions - 2019 ALK Pos, Developing Resistance to ALK Inhibitors and Next Steps

Howard (Jack) West, MD

Case Based Panel Discussion - 2019 ALK Positive with Brain Mets, Radiation before ALK Inhibitor?

Howard (Jack) West, MD

Case Based Panel Discussion - 2019 ALK Positive, Progression after Success on ALK Inhibitor

Howard (Jack) West, MD

Case Based Panel Discussion 2019 - Progression Post ALK Inhibitor - Role For Combination Therapies?

Howard (Jack) West, MD

Case Based Panel Discussion –ALK Positive, High PD-L1:First Line Treatment for Competing Targets

Howard (Jack) West, MD

Case Based Panel Discussion NSCLC – Does a Positive HER2 Mutation Effect Treatment Decisions?

Howard (Jack) West, MD

Case Based Panel Discussions 2019 - Lung Cancer

EGFR Mutations: Driver Mutations and Biomarker-Driven Therapies in NSCLC

Case Based Panel Discussion - EGFR - Exon 20 Mutation, Treatment, Targeted Therapy, Clinical Trials

Howard (Jack) West, MD

Copyright © 2021 Global Resource for Advancing Cancer Education
Site by Freelock